These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35341513)

  • 21. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Self-assembled polydopamine nanoparticles improve treatment in Parkinson's disease model mice and suppress dopamine-induced dyskinesia.
    Vong LB; Sato Y; Chonpathompikunlert P; Tanasawet S; Hutamekalin P; Nagasaki Y
    Acta Biomater; 2020 Jun; 109():220-228. PubMed ID: 32268242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease.
    Nakazato T; Akiyama A
    Brain Res; 2002 Mar; 930(1-2):134-42. PubMed ID: 11879803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
    Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
    J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spectroscopic study of L-DOPA and dopamine binding on novel gold nanoparticles towards more efficient drug-delivery system for Parkinson's disease.
    Kalčec N; Peranić N; Barbir R; Hall CR; Smith TA; Sani MA; Frkanec R; Separovic F; Vinković Vrček I
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Mar; 268():120707. PubMed ID: 34902692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists.
    Sarre S; Vandeneede D; Ebinger G; Michotte Y
    J Neurochem; 1998 Apr; 70(4):1730-9. PubMed ID: 9523592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of dopamine metabolites on locomotor activities and on the binding of dopamine: relevance to the side effects of L-dopa.
    Charlton CG; Crowell B
    Life Sci; 2000 Apr; 66(22):2159-71. PubMed ID: 10834300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa: effect on cell death and the natural history of Parkinson's disease.
    Olanow CW
    Mov Disord; 2015 Jan; 30(1):37-44. PubMed ID: 25502620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota.
    Wang Y; Tong Q; Ma SR; Zhao ZX; Pan LB; Cong L; Han P; Peng R; Yu H; Lin Y; Gao TL; Shou JW; Li XY; Zhang XF; Zhang ZW; Fu J; Wen BY; Yu JB; Cao X; Jiang JD
    Signal Transduct Target Ther; 2021 Feb; 6(1):77. PubMed ID: 33623004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The medical treatment of Parkinson disease from James Parkinson to George Cotzias.
    Fahn S
    Mov Disord; 2015 Jan; 30(1):4-18. PubMed ID: 25491387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-dose L-dopa increases upper brainstem GABA in Parkinson's disease: A preliminary study.
    Song Y; Gong T; Xiang Y; Mikkelsen M; Wang G; Edden RAE
    J Neurol Sci; 2021 Mar; 422():117309. PubMed ID: 33548666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid synthesis of microwave-assisted zinc oxide nanorods on a paper-based analytical device for fluorometric detection of l-dopa.
    Lin YH; Yeh YC
    Colloids Surf B Biointerfaces; 2021 Nov; 207():111995. PubMed ID: 34303994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
    Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factors.
    Lai CT; Yu PH
    Biochem Pharmacol; 1997 Feb; 53(3):363-72. PubMed ID: 9065740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.